Isabel Jakobs
Rechtsanwältin (Lawyer), Associated Partner

Dr Isabel Jakobs advises German and international companies on product liability and product safety law, i.a. with a particular focus on the life sciences sector. She acts for clients before and outside the courts in liability disputes and administrative proceedings involving the authorities. In addition, she advises clients on product law requirements for the German and European market and also assists in transactions with a view to product regulation. Isabel is the author of academic publications on various product safety and product liability topics. She also gives guest lectures on quality and process management at the University of Kassel.
Distinctions
- Recommended for Dispute Resolution/Product Liability and Health by Legal 500 (2022/2023).
Career
Lectures
- "Quality and Law"; regular guest lecture at the University of Kassel
Publications
- Germany - Liability for Medicinal Products and the Right to Disclosure under German Law" (co-author, in European Pharmaceutical Law Review 2/2018)
- Comment on a decision of Kammergericht Berlin, ruling of 23 May 2016, 20 U 207/15 (co-author, in MPR 2/2018)
- Betreiberspezifische Aspekte der neuen Europäischen Medizinprodukteverordnung (co-author, in GuP 2017)
- Rückruf fehlerhafter Medizinprodukte bei deliktischer Produkthaftung, Dissertationsschrift (PhD thesis), published in „Augsburger Schriften zum Arzneimittel und Medizinprodukterecht"
- Software als Medizinprodukt: Haftungs- und versicherungsrechtliche Aspekte (co-author, in MPR 1/2019)
- Messverfahren von Emissionshöchstwerten bei Zigaretten und Zulässigkeit des Verweises auf (private) ISO-Normen“ (comment on ECJ ruling, February 22, 2022 - C-160/20; in ZfPC 3/2022).
- Doctor A.I.: Künstliche Intelligenz und Medizinprodukte, (in Robotik und Produktion, 21 April 2022)
- Poland: Advertising Medical Devices – The New European and Polish Regulatory Framework (co-author, in CEE Legal Matters, 7 February 2023)
Well
informed
Subscribe to our newsletter now to stay up to date on the latest developments.
Subscribe now